Browse News
Filter News
Found 806,079 articles
-
Citing a JAMA study that found Ozempic could be profitably produced at under $5 per month, Senator Bernie Sanders on Wednesday called on Novo Nordisk to lower prices for the diabetes treatment and the weight-loss drug Wegovy.
-
After an initial rejection due to safety issues, followed by a dispute and deferred actions, Akebia Therapeutics on Wednesday finally won the FDA’s nod for vadadustat as a treatment for anemia caused by chronic kidney disease.
-
Continuing 2024’s biotech initial public offering rally, Boundless Bio will debut Thursday on the Nasdaq with the proceeds used to advance its pipeline of extrachromosomal DNA cancer assets.
-
To avoid overextending yourself and harming your work-life balance, how should you set and maintain boundaries at work?
-
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
3/28/2024
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the supplemental New Drug Application (“sNDA”) for savolitinib, in adult patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) with mesenchymal epithelial transition factor (“MET”) exon 14 skipping alteration, has been accepted for review by the China National Medical Products Administration (NMPA).
-
An ActRIIA Fusion Protein Got FDA Approved for PAH Treatment
3/28/2024
On March 26th, the US FDA granted approval for Merck’s WINREVAIR™ (sotatercept-csrk), marking a significant milestone in pulmonary arterial hypertension (PAH) treatment.
-
Magritek makes benchtop NMR available for drug analysis in forensic labs
3/28/2024
The market-leading benchtop Nuclear Magnetic Resonance (NMR) developer, Magritek, introduces its qIDsolve benchtop NMR software package, which is quickly being adopted by forensics laboratories around the world.
-
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering - March 28, 2024
3/28/2024
Praxis Precision Medicines, Inc. announced the pricing of its underwritten public offering of 3,318,585 shares of its common stock at a public offering price per share of $56.50 and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 221,238 shares of common stock at a purchase price of $56.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant.
-
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
3/28/2024
Stoke Therapeutics, Inc. announced the pricing of its upsized underwritten public offering of 5,555,557 shares of its common stock at a price to the public of $13.50 per share and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to an aggregate of 3,703,730 shares of its common stock at a price to the public of $13.4999.
-
Promising First-In-Human Phase 1B Clinical Study Data from VRON-0200, a Novel, First-in-Class Checkpoint Modifier Immunotherapy for Chronic Hepatitis B Virus Functional Cure, Presented as Late-Breaker at 2024 APASL Global Liver Meeting
3/28/2024
Virion Therapeutics, LLC announced promising safety results from the first-ever human data from its novel, first-in-class, checkpoint modifier immunotherapy, VRON-0200, for HBV functional cure, presented by Professor Grace Wong, M.D., from the Chinese University of Hong Kong, as a late breaker oral presentation at the 33rd Annual Meeting of APASL in Kyoto, Japan.
-
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
3/28/2024
Zymeworks Inc. announced the appointment of Dr. Neil Gallagher to its board of directors effective April 2, 2024.
-
Sirnaomics Announces 2023 Annual Results
3/28/2024
Sirnaomics Ltd., a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, has announced its audited annual results for the year ended 31 December 2023.
-
Tigermed Reports Full Year 2023 Results
3/28/2024
Hangzhou Tigermed Consulting Co., Ltd., a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2023.
-
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
3/28/2024
Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® and the future of photomedicine.
-
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Adults
3/28/2024
Merck, known as MSD outside of the United States and Canada, announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-containing chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable non-small cell lung cancer at high risk of recurrence in adults.
-
Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development
3/28/2024
Intravacc and Primrose Bio announced a strategic partnership to enhance the development and supply of conjugate vaccines.
-
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
3/28/2024
Akebia Therapeutics®, Inc. announced that the U.S. Food and Drug Administration has approved Vafseo® Tablets for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months.
-
CLS Americas Announces ROSE Urology will use TRANBERG Laser to Treat Prostate Cancer Patients with Focal Laser Ablation
3/28/2024
Clinical Laserthermia Systems Americas, Inc. announced that ROSE Urology, LLC, located in Vero Beach, Florida, will begin using the TRANBERG™ Thermal Therapy System to treat prostate cancer patients.
-
Erasca Announces $45 Million Oversubscribed Private Placement Financing
3/28/2024
Erasca, Inc. announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell 21,844,660 shares of its common stock in an oversubscribed private placement at a price of $2.06 per share.
-
China Medical System (867.HK)2023 Annual Results: Despite of the Temporary Financial Performance Pressure Fresh Catalysts Emerged from Successive Innovation Breakthroughs
3/28/2024
On March 27, 2024, China Medical System released its 2023 annual results. The Company recorded a turnover of RMB8,013 million, a year-on-year decrease of 12.4%; in the case that all medicines were directly sold by the Group, the turnover would be RMB 9,472 million, a year-on-year decrease of 9.8%.